MANUEL
PRAGA TERENTE
Profesor emérito
Universitat de Barcelona
Barcelona, EspañaUniversitat de Barcelona-ko ikertzaileekin lankidetzan egindako argitalpenak (19)
2023
-
Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy
Kidney360, Vol. 4, Núm. 5, pp. 659-672
-
Consensus document of the Spanish Group for the Study of the Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis
Nefrologia, Vol. 43, Núm. 1, pp. 6-47
-
Thrombotic microangiopathy in patients with malignant hypertension
Nephrology Dialysis Transplantation, Vol. 38, Núm. 5, pp. 1217-1226
2022
-
C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies
Nephrology Dialysis Transplantation, Vol. 37, Núm. 11, pp. 2128-2137
-
Development and validation of a nomogram to predict kidney survival at baseline in patients with C3 glomerulopathy
Clinical Kidney Journal, Vol. 15, Núm. 9, pp. 1737-1746
-
Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 37, Núm. 7, pp. 1270-1280
-
Saving the kidneys in the lupus patient: Beyond immunosuppression, the need to collaborate across multiple disciplines
European Journal of Internal Medicine, Vol. 99, pp. 19-21
2021
-
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy
Kidney International, Vol. 99, Núm. 4, pp. 986-998
-
Validation of a Histologic Scoring Index for C3 Glomerulopathy
American Journal of Kidney Diseases, Vol. 77, Núm. 5, pp. 684-695.e1
2020
-
Mycophenolate mofetil in c3 glomerulopathy and pathogenic drivers of the disease
Clinical Journal of the American Society of Nephrology, Vol. 15, Núm. 9, pp. 1287-1298
-
Risk factors for non-diabetic renal disease in diabetic patients
Clinical Kidney Journal, Vol. 13, Núm. 3, pp. 380-388
2019
-
Complement activation and thrombotic microangiopathies
Clinical Journal of the American Society of Nephrology, Vol. 14, Núm. 12, pp. 1719-1732
-
Treatment for refractory lupus nephritis: Rituximab vs triple target therapy
Autoimmunity Reviews, Vol. 18, Núm. 12
2018
2017
-
Elevated factor H–related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy
Kidney International, Vol. 92, Núm. 4, pp. 953-963
2014
-
Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 9, pp. 583-597
-
Resumen ejecutivo del documento de consenso sobre el manejo de la patología renal en pacientes con infección por VIH
Nefrologia, Vol. 34, Núm. 6, pp. 768-788
2012
-
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
Annals of the Rheumatic Diseases, Vol. 71, Núm. 11, pp. 1771-1782
2011
-
Validation of a therapeutic scheme for the treatment of resistant hypertension
Journal of the American Society of Hypertension, Vol. 5, Núm. 6, pp. 498-504